Pyxis Oncology Announces The Appointment Of Alex Kane As Senior Vice President Of Investor Relations & Capital Markets

Pyxis Oncology, Inc., a clinical-stage company developing antibody-drug conjugate (ADC) therapies for hard-to-treat cancers, has announced the appointment of Alex Kane, MBA, as Senior Vice President of Investor Relations & Capital Markets, effective immediately. 

Mr. Kane brings two decades of experience in investor relations, strategic communications, and equity capital markets within the life sciences sector. He joins Pyxis Oncology from Guggenheim Securities, where he served as Vice President of Equity Capital Markets, advising biotechnology clients on financing strategies and equity transactions.

Prior to that, Mr. Kane held senior investor relations and communications roles at Praxis Precision Medicines and PTC Therapeutics, where he managed initial public offerings (IPOs), secondary offerings, and long-term investor engagement programs. Earlier in his career, he held leadership positions at W2O Group, NASDAQ, and Thomson Reuters, providing guidance to public and private life sciences companies on capital markets strategy, investor targeting, and corporate positioning.

Mr. Kane earned his MBA in Finance and Entrepreneurship from the NYU Stern School of Business and holds a BA in International Political Economy from Colorado College.

“Alex brings deep expertise in investor relations and capital markets, and he is highly regarded for his ability to communicate value creation opportunities effectively to the investment community,” said Lara S. Sullivan, M.D., President, Chief Executive Officer, and Chief Medical Officer of Pyxis Oncology. “His insights and strong relationships will be critical as Pyxis Oncology advances MICVO’s clinical programs and prepares for upcoming milestones.”

This appointment strengthens Pyxis Oncology’s leadership team as the company continues to advance its clinical-stage ADC programs targeting difficult-to-treat cancers and seeks to enhance engagement with the investor community.